Pharmacology药理学---浙江大学教学信息化平台.pptVIP

Drugs for treatment of respiratory diseases Huifang Tang Department of pharmacology Zhejiang University, school of medicine tanghuifang@zju.edu.cn Research building C422 2012-3-28 Adrenocorticoid drugs Adrenocortical hormones Mineralocorticoids Glucocorticoids (Glucocorticosteroids) Sex hormones Adverse effects Local: oropharyngeal candidiasis－using spacer Systemic effects Hypercorticism-like syndrome: central obesity (moon face, buffalo hump, etc.); hypertension; glycosuria, hypokalemia; etc. Increasing susceptibility to infections Ingestive system: peptic ulcers, etc. Cardiovascular system: hypertension, arteriosclerosis Myopathy and osteoporosis: vertebral compression fractures, spontaneous fractures, especially in postmenopausal women Adrenal suppression Other inhibitors of mediator release: Sodium nedocromil(萘多罗米钠) Inhibiting mediators release from mast cell or other cells, the effect is better than disodium cromoglycate. Ketotifen(酮替芬) Inhibiting mediators release, and antagonizing H1 receptor. Leukotriene receptor antagonists (LTRA) (CysLT1 receptor antagonist) montelukast (孟鲁司特) zafirlukast (扎鲁司特) 5-lipoxygenase inhibitors zileuton (齐留通) Leukotriene metabolism pathway LTC4, LTD4, LTE4----CysLT1 receptor bronchoconstrictors, increase microvascular permeability, mucus secretion LTB4----BLT receptor chemoattractant for neutrophils Zafirlukast (Accolate, 扎鲁司特) an oral LTRA Reducing constriction of the airways and build-up of mucus in the lungs and inflammation of the breathing passages. Clinical use: twice daily maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. Montelukast (Singulair and Montelo-10, 孟鲁司特) it blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. reduces the